Gene Expression in Normal Tissue and Tumor Tissue From Patients Who Have Undergone Surgery For Kidney Cancer
Status: | Terminated |
---|---|
Conditions: | Cancer, Cancer, Kidney Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any - 120 |
Updated: | 4/21/2016 |
Start Date: | September 2003 |
End Date: | June 2012 |
Renal Cell Cancer Tumor Markers
RATIONALE: Studying the genes and proteins expressed in tissue samples from patients with
cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This laboratory study is evaluating gene and protein expression in normal tissue
and tumor tissue from patients who have undergone surgery for kidney cancer.
cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This laboratory study is evaluating gene and protein expression in normal tissue
and tumor tissue from patients who have undergone surgery for kidney cancer.
OBJECTIVES:
Primary
- Determine the expression levels of novel genes and proteins (HFARP, HAMGR28, HE9NG77)
in frozen normal tissue and tumor tissue samples from patients who have undergone
nephrectomy for renal cell cancer.
- Correlate gene and protein expression levels with disease stage, tumor size, and
pathology reports (e.g., cell type, grade, and tissue architecture) in order to
evaluate the rate of gene and protein expression as targets for future therapeutic
interventions.
Secondary
- Compare proteomic screening of potential biomarkers using existing plasma and/or urine
samples from patients with renal cell cancer or breast cancer stored in the CCCWFU
Tumor Tissue Core with tissue samples from patients enrolled in this study.
OUTLINE: Normal and tumor tissue collected from patients who have undergone nephrectomy and
diagnostic and therapeutic intervention for renal cell cancer is analyzed for
histopathological expression and compared to normal kidney cells by northern blot. Tissue
samples are evaluated by RNA and protein extraction and analyzed by gel electrophoresis,
blotting, and phosphor-imaging for induction or suppression of genes and protein levels.
These data are correlated with clinical stage, tumor size, and histopathological grade and
architecture of the patient's disease.
Primary
- Determine the expression levels of novel genes and proteins (HFARP, HAMGR28, HE9NG77)
in frozen normal tissue and tumor tissue samples from patients who have undergone
nephrectomy for renal cell cancer.
- Correlate gene and protein expression levels with disease stage, tumor size, and
pathology reports (e.g., cell type, grade, and tissue architecture) in order to
evaluate the rate of gene and protein expression as targets for future therapeutic
interventions.
Secondary
- Compare proteomic screening of potential biomarkers using existing plasma and/or urine
samples from patients with renal cell cancer or breast cancer stored in the CCCWFU
Tumor Tissue Core with tissue samples from patients enrolled in this study.
OUTLINE: Normal and tumor tissue collected from patients who have undergone nephrectomy and
diagnostic and therapeutic intervention for renal cell cancer is analyzed for
histopathological expression and compared to normal kidney cells by northern blot. Tissue
samples are evaluated by RNA and protein extraction and analyzed by gel electrophoresis,
blotting, and phosphor-imaging for induction or suppression of genes and protein levels.
These data are correlated with clinical stage, tumor size, and histopathological grade and
architecture of the patient's disease.
Inclusion Criteria:
- Histologically confirmed renal cell cancer
- Clinical staging (if available)
- Underwent nephrectomy for renal cell cancer
We found this trial at
1
site
1 Medical Center Blvd
Winston-Salem, North Carolina 27103
Winston-Salem, North Carolina 27103
(336) 716-2011
Wake Forest University Comprehensive Cancer Center Our newly expanded Comprehensive Cancer Center is the region’s...
Click here to add this to my saved trials